Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

Similar documents
The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Assist Devices in STEMI- Intra-aortic Balloon Pump

Mechanics of Cath Lab Support Devices

Mechanics of Cath Lab Support Devices

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017

Bridging With Percutaneous Devices: Tandem Heart and Impella

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

DECLARATION OF CONFLICT OF INTEREST

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

Percutaneous Mechanical Circulatory Support Devices

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

Management of Acute Shock and Right Ventricular Failure

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Circulatory Support: From IABP to LVAD

Case - Advanced HF and Shock (INTERMACS 1)

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

Rhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale

Introduction to Acute Mechanical Circulatory Support

Cardiogenic Shock. Carlos Cafri,, MD

Ventricular Assisting Devices in the Cathlab. Unrestricted

Cardiogenic Shock Protocol

Disclosures. Objectives 10/11/17. Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock. I have no disclosures to report

Cardiogenic Shock in Acute MI

Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

Definition. Low-cardiac-output state resulting in life threatening end-organ hypoperfusion. Criteria: MAP 30 mm Hg lower than baseline)

Acute Myocardial Infarction Complicated by Cardiogenic Shock

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

Hemodynamic Monitoring and Circulatory Assist Devices

AllinaHealthSystem 1

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4

To ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW

Ted Feldman, M.D., MSCAI FACC FESC

Acute Mechanical Circulatory Support Right Ventricular Support Devices

The majority of patients with cardiomyopathy

Extra Corporeal Life Support for Acute Heart failure

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017

เอกราช อร ยะช ยพาณ ชย

Echo assessment of patients with an ECMO device

ECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan

CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)

Who is the high risk patient?

AATS/Cardiothoracic Critical Care Symposium

Section 6 Intra Aortic Balloon Pump

Understanding the Pediatric Ventricular Assist Device

Surgical Options for Temporary MCS

Hardware in the Chest - From VADs to Valves

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Update on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada

MANAGEMENT OF CARDIOGENIC SHOCK

Right Ventricular Failure: Prediction, Prevention and Treatment

CENTRAL ECMO WHEN AND HOW? RANJIT JOHN, MD UNIVERSITY OF MINESOTA

Implantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013

Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ

Management of Cardiogenic shock. Prof. Christian JM Vrints

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

The World s Smallest Heart Pump

PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR

Andrew Civitello MD, FACC

MCS for Acute Heart Failure Eric Adler MD Associate Professor of Medicine Medical Director Cardiac Transplant

LV Distension and ECLS Lungs

Cardiogenic Shock and Initiatives to Reduce Mortality

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support

CABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock

Acute heart failure: ECMO Cardiology & Vascular Medicine 2012

Relax and Learn At the Farm 2012

Which mechanical assistance for cardiogenic shock?

A National Cardiogenic Shock Initiative (CSI):

Recovering Hearts. Saving Lives.

Cath Lab Essentials: Basic Hemodynamics for the Cath Lab and ICU

Medical Management of Acute Heart Failure

Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας

Introduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring

Cardiac Interventions

ECMO and VAD implantation

Complications of Acute Myocardial Infarction

DECLARATION OF CONFLICT OF INTEREST

Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies

Impedance Cardiography (ICG) Method, Technology and Validity

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities

High Risk PCI for Heart Failure

CHF ICU to community. Disclosure slide CHF. Diagnosis. Diagnosis. Diagnostic modalties Therapeutic modalities. Talks. Advisory boards.

Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?

Total Artificial Hearts and Implantable Ventricular Assist Devices

ECMO as a Bridge to Heart Transplant in the Era of LVAD s.

Impella Ins & Outs. CarVasz November :45 12:15

Cardiogenic shock: Current management

Hemodynamic improvement upon levosimendan treatment in low cardiac output patients following coronary artery bypass graft

Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio

I Was Too Late With Device Placement

Acute Circulatory Support Should We or Shouldn t We?

FUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART

Name of Policy: Ventricular Assist Devices and Total Artificial Hearts

Recognizing the Need to Support A Failing Right Ventricular Role of Mechanical Support

Detailed Order Request Checklists for Cardiology

Transcription:

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology

Disclosures I have no financial or other conflicts of interest to report.

Cardiogenic Shock Inadequate end organ perfusion due to a reduced cardiac output despite adequate circulatory volume AMS; Cold, clammy skin; Oliguria; Increased serum lactate 1. Cardiac Index (CI) CI < 1.8 L/min/m 2 CI < 2.2 L/min/m 2 with inotropic/pressor support 2. PCWP > 15 mmhg or LVEDP >18 3. Systolic Blood Pressure (SBP) SBP < 90 mmhg for at least 30 mins SBP > 90 mmhg with inotropic/pressor support

Causes of Cardiogenic Shock Cardiology Clinics, 2013; 31(4): 567-580,

Physiology of Cardiogenic Shock: A Downward Spiral Myocardial Infarction Blood pressure [ Vasodilation [SVR ] Cardiac output [ CO] Hemodynamic support BP 10 Reperfusion : PCI or CABG 5 Death 4 SVR BP] 11 Venous return 9 6 NO synthesis CO 3 12 15 1 Damaged heart muscle 14 2 13 7 8 CO & BP Inflammatory activation (TNF-α, IL-6) Myocardial perfusion Myocardial ischemia Coronary artery perfusion Myocardial ischemia Reducing inflammatory response:?

Mortality (%) Emergency revascularisation - SHOCK Trial 70% 60% 50% p=0.11 47% 56% 50% 63% p=0.03 53% 66% ERV IMS 40% 30% 20% 10% 0% 30 days (n=302) 6 months (n=301) 12 months (n=299) 85% of survivors NYHA Class I/II at 12 months after early revascularization or initial medical stabilization Hochman JAMA 2000;285:190

Heart muscle can recover with support High Potential of heart muscle recovery, Gain in Ejection Fraction Low Potential of heart muscle recovery, Loss in Ejection Fraction 9 New England Journal of Medicine: 2003; 348:2007-18

The primary goals of nondurable MCS devices are to acutely: 1. Increase vital organ perfusion 2. Augment coronary perfusion 3. Reduce ventricular volume and filling pressures, thereby reducing wall stress, stroke work, and myocardial oxygen consumption

Intra-Aortic Balloon Pump Introduced in 1968 (Kantrowitz) First true percutaneous support device Cheapest, most common (20% of all cardiogenic shock cases), CO 0.5L/min Stabilize pt, but not full support No outcome benefit Hemodynamic Effects Diastolic pressure CO/cardiac workload MAP LV Wall Tension PCWP Oxygen Demand LV Volume Coronary Blood Flow

Optimal IABP function is determined by four factors: 1. The magnitude of diastolic pressure augmentation 2. The magnitude of reduced systolic pressure 3. The magnitude of volume displacement 4. The timing of balloon inflation and deflation Curr Cardiol Rep. 2015; 17:40

Nair et al Journal of Invasive Cardiology 2011

IABP-Shock II Trial: Results Primary Study Endpoint: 30-day Mortality (IABP in Cardiogenic Shock and Primary PCI) Thiele H et al. NEJM 2012;367:1287

Indications for IABP High Risk PCI Cardiogenic Shock Refractory Ischemia Left Main 3 Vessel CAD VT/VFib MR or VSD after MI Severe CHF? Bridge to Transplant Pre-operative stabilization

Contraindication to IABP Severe Peripheral vascular disease Aortic regurgitation Aortic Dissection PDA HOCM Heparin intolerance Bleeding Diathesis Sepsis

Complications of IABP Vascular access bleeding/complications Limb ischemia Infection Thrombocytopenia Migration and aortic arch trauma Other non-vascular (CVA, embolization of cholesterol, balloon rupture) Air embolism risk (reduced by using helium gas)

Hemodynamic Advantage of pvad vs. IABP pvad IABP Directly unload the left ventricle Reduce myocardial workload and oxygen consumption Increase cardiac output and coronary and end- organ perfusion +++ - +++ ++ +++ +

Impella Continuous axial flow pump Simple insertion Increases cardiac output & unloads LV LP 2.5 CO 2.5 L/min CP 4.0 L/min 14 F percutaneous LP 5.0 21 F surgical cutdown; Maximum 5L flow

Impella Insertion

Principles of Impella Design Mimic Heart s Natural Function Inflow (ventricle) Outflow (aortic root) EDV, EDP AOP Flow O 2 Demand Myocardial Protection O 2 Supply Cardiac Power Output Systemic Hemodynamic Support Naidu S S Circulation 2011;123:533-543

IMPELLA Unloads Actively the Ventricle, Reduces Work Systemic Loads and Hemodynamic Increases Cardiac Support Output CO Increase Valgimigli et al.,cath Cardiov Interv (2005) End-Diastolic LV Pressure Impella 2.5 18 mmhg High risk PCI patient Demonstrated net CO increase with simultaneous ventricular unloading Pump Off 11 mmhg Pump On End-Diastolic Stroke Volume 94 ml Pump Off 6.0 L/min 76 ml Native CO Pump On Total Cardiac Output 6.0 L/min LV Pump Off 7.4 L/min Impella (2.4) 7.4 L/min pump 5.0 LV 9/21 Pump On M.Valgimigli et al.,catheterization & Cardiovascular Interventions 65:263 267 (2005)

Contraindications Mural thrombus in the LV Presence of a mechanical aortic valve Aortic valve stenosis (AVA 0.6cm2) Moderate to severe aortic insufficiency Severe PAD VSD Complications Hemolysis May respond to repositioning the device Persistent hemolysis associated with acute kidney injury Bleeding Limb ischemia/vascular injury Stroke

Case 52 year old female lap cholecystectomy complicated by injury to the common bile duct and sepsis. Patient become acutely tachycardic to 160s and hypoxic.

TandemHeart Left atrial-to-femoral arterial LVAD 21F venous transseptal cannula 17F arterial cannula Maximum flow 4L/min Hemodynamic Effects CO MAP PCWP

Transseptal puncture 21 F cannula in LA

TandemHeart Cannula Venous cannula arterial return cannula

Cardiac Index (l/min/m2) Required Transfusion (%) TandemHeart Shock Study 30-day Mortality (%) Limb Ischemia (%) 2.4 2.2 2.0 1.8 1.6 1.4 Cardiac Index 0 1.5 IABP Pre p=0.4 1.7 n=20 n=21 PerVAD Post p=0.005 1.7 IABP 2.3 PerVAD 60 50 40 30 20 10 30-day Mortality 0 45% 9/20 IABP p=0.8 43% 9/21 PerVAD 100 90 80 70 60 50 40 0 Transfusion p=0.002 40% 8/20 IABP 90% 19/21 PerVAD 60 50 40 30 20 10 0 Limb Ischemia 0/20 IABP Thiele and al. Eur. Heart Journal 2005 Jul;26(13):1276-83 p=0.009 0% 33% 7/21 PerVAD

Extracorporeal Membrane Oxygenation (ECMO)

Cannulation Femoral vein cannulated with 21-25Fr catheter tip in the right atrium. Femoral artery cannula 17-21 Fr inserted to the taper with the tip at the common iliac artery or lower aorta. Distal antegrade perfusion cannula inserted into common femoral artery to prevent distal limb ischemia. Usual size 5-9 Fr

Peripheral Cannulation Retrograde peripheral flow leads to admixing in the arch If there is respiratory insufficiency, the heart will pump poorly oxygenated blood to the coronaries and proximal arch vessels while ECMO supplies oxygenated blood to the rest of the body.

Advantages and Disadvantages Relatively Inexpensive (as compared to Impella/TandemHeart) Double the cost of conventionally treated patients ($65K) Favorable lifetime predicted cost-utility Minimally invasive (peripheral cannulation) Bedside deployment Biventricular support Pulmonary support Labor intensive (ACT monitoring, bedside monitoring, management) Patient is immobilized LV distention High complication risk (57%)

Bridge to Nowhere Absolute Unrecoverable heart and not a candidate for transplant or VAD Presence of severe chronic organ failure Severe brain injury OR Prolonged CPR Severe peripheral vascular disease Severe aortic insufficiency Relative Obesity Malignancy Contraindication to anticoagulation Advanced age >75 Compliance (financial, cognitive, psychiatric, or social limitations)

71 yo M 4h intermittent chest pain, light headedness, pallor, sweating. Inferior STEMI. Left Coronary System has mild CAD. RCA is 100%. JVD 12cm. Fluids, Dopamine given. BP 72/55, HR 68bpm. What now? IABP? LVAD?

Percutaneous Biventricular Acute MCS Support Configuration Kapur et al. Circ. 2017;136:314-326

Mechanical circulatory support for RV failure Kapur et al. Circ. 2017;136:314-326

Approach to Cardiogenic Shock Consider IABP in: Cardiogenic shock (mild) Moderate to severe cardiogenic shock, on inotropes and vasopressors: Consider Impella (CP, 5.0L), TandemHeart, ECMO Biventricular cardiogenic shock: Consider ECMO or combined percutaneous LVAD/RVAD

Optimal Timing (early, late, futility) Optimal Therapy Optimal Support Device Optimal management of device (avoiding complications) Euro Heart J(2015) 36, 1223 1230

Thank You